Overview

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences